Provides broad overview of Company's research and early development programs expected to continue to fuel future growth ...

Dispatch Bio is building a system that could broaden treatment for a wide variety of tumors, and it’s about to start testing ...

Provides broad overview of Company's research and early development programs expected to continue to fuel future growthHighlights validation of T-cell engager modality with mRNA-2808 in multiple myelo ...

The renal cancer pipeline presents key opportunities in developing novel therapies targeting immunosuppression and oncogenic pathways. Notable advancements include combinations like Quavonlimab with ...

Eating a range of foods with high antioxidant content may be a big factor in living a longer life, according to research. Here are some of the flavonoid-rich staples to consider adding to your diet.

A quiet layer of biology is beginning to change how health is understood, and it sits on the surface of nearly every cell in ...

The SUBITO trial, presented by Rianne L Seefat and colleagues in The Lancet Oncology,1 revisits the long-standing debate ...

Natera delivers robust revenue growth, raising 2026 guidance to $2.74–$2.82 billion, but remains unprofitable. Read more on ...

The Minimal Residual Disease pipeline presents key opportunities for drug development, highlighting promising therapies in various trial phases. Companies like AmMax Bio and Genentech leverage ...

But the climate and weather on this great continent is amazingly varied. The Sahara desert can often reach temperatures of 50 ...

Replimune Group, Inc. nears a pivotal FDA AdCom for RP1 ahead of an Aug 2, 2026 decision. Click for this REPLY stock update ...

Over the last couple of decades, cancer has become arguably the most pressing health concern in India. According to ...